—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BridgeBio Pharma Inc (BBIO) — Technical state

As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 35 out of 100 (momentum 49 · quality 21 · valuation 11), as of 2026-11-03.
  • Signal: Recovery attempt under the 200-day — Trades +6.9% vs the 50-day and +3.1% vs the 200-day average, 19.7% below the 52-week high and +24.5% off the 52-week low; a death cross printed 12 sessions ago. Computed from daily closes. (as of 2026-11-02)
  • Trend: BridgeBio Pharma Inc trades 6.9% above its 50-day and 3.1% above its 200-day moving average. (as of 2026-11-02)

BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the BBIO overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Recovery attempt under the 200-day

Trades +6.9% vs the 50-day and +3.1% vs the 200-day average, 19.7% below the 52-week high and +24.5% off the 52-week low; a death cross printed 12 sessions ago. Computed from daily closes.

The moving-average stack

Continue: the BBIO chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-02

Quick answers

What is the current Closelooknet signal on BBIO?

Recovery attempt under the 200-day — Trades +6.9% vs the 50-day and +3.1% vs the 200-day average, 19.7% below the 52-week high and +24.5% off the 52-week low; a death cross printed 12 sessions ago. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is BBIO above its 50-day and 200-day moving averages?

As of 2026-11-02, BridgeBio Pharma Inc trades +6.9% above its 50-day and +3.1% above its 200-day average, with the 20-day +10.3% away.

How far is BBIO from its 52-week high?

19.7% below the 52-week high and 24.5% above the 52-week low, as of 2026-11-02.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.